Cannabidiol derivatives and medical use thereof, in particular to the compounds represented by general formula (I), or stereoisomers, solvates, metabolites, prodrugs, pharmaceutically acceptable salts or cocrystals thereof, wherein the definitions of substituents in general formula (I) are the same as those in the description

##STR00001##

A compound represented by the general formula (V)

##STR00001##

wherein all the symbols are as defined in the specification, has an improved balance of the agonist activity against the S1P.sub.5 receptor relative to the S1P.sub.1 receptor, and can thus serve as a therapeutic agent for S1P.sub.5-mediated diseases such as schizophrenia and Binswanger's disease and other neurodegenerative diseases.

A compound represented by the general formula (V)

##STR00001##

wherein all the symbols are as defined in the specification, has an improved balance of the agonist activity against the S1P.sub.5 receptor relative to the S1P.sub.1 receptor, and can thus serve as a therapeutic agent for S1P.sub.5-mediated diseases such as schizophrenia and Binswanger's disease and other neurodegenerative diseases.

Decalin derivative compounds of formula (I) are provided, including processes for preparation thereof, and pharmaceutical compositions including the decalin derivative compounds. Methods are provided for treating blood related disorders, such as sickle cell anemia, in a subject in need thereof using a compound of formula (I).

##STR00001##

Decalin derivative compounds of formula (I) are provided, including processes for preparation thereof, and pharmaceutical compositions including the decalin derivative compounds. Methods are provided for treating blood related disorders, such as sickle cell anemia, in a subject in need thereof using a compound of formula (I).

##STR00001##

A compound represented by the general formula (V) ##STR00001##
wherein all the symbols are as defined in the specification, has an improved balance of the agonist activity against the S1P.sub.5 receptor relative to the S1P.sub.1 receptor, and can thus serve as a therapeutic agent for S1P.sub.5-mediated diseases such as schizophrenia and Binswanger's disease and other neurodegenerative diseases.

A compound represented by the general formula (V) ##STR00001##
wherein all the symbols are as defined in the specification, has an improved balance of the agonist activity against the S1P.sub.5 receptor relative to the S1P.sub.1 receptor, and can thus serve as a therapeutic agent for S1P.sub.5-mediated diseases such as schizophrenia and Binswanger's disease and other neurodegenerative diseases.

Decalin derivative compounds of formula (I) are provided, including processes for preparation thereof, and pharmaceutical compositions including the decalin derivative compounds. Methods are provided for treating blood related disorders, such as sickle cell anemia, in a subject in need thereof using a compound of formula (I). ##STR00001##

Decalin derivative compounds of formula (I) are provided, including processes for preparation thereof, and pharmaceutical compositions including the decalin derivative compounds. Methods are provided for treating blood related disorders, such as sickle cell anemia, in a subject in need thereof using a compound of formula (I). ##STR00001##

The present invention provides methods for inhibiting respiratory complex III in a cell. The present invention also provides methods for treating cancer in a subject.